CRESTOR Demonstrates CV Risk Reduction in a Large Statin Outcomes Study
Results also showed that for patients in the trial taking rosuvastatin:
- the combined risk of heart attack, stroke or CV death was reduced by nearly half (47%, p<0.001).
- risk of heart attack was cut by more than half (54%, p<0.001).
- risk of stroke was cut by nearly half (48%, p=0.002).
- total mortality was significantly reduced by 20% (p=0.02).
These results were accompanied by a median LDL-C reduction of 50% (p<0.001) resulting in an on-treatment median LDL-C of 55 mg/dL.
On the basis of the data, if the results are projected over a period of 5 years, 25 patients would need to be treated to prevent one major cardiovascular event (NNT=25).
The JUPITER results were published online by the New England Journal of Medicine.
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.